These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 2217426)

  • 21. Bladder cancer: clinical practice.
    Rabinowits G; Laber DA
    J Ky Med Assoc; 2009 Apr; 107(4):129-33. PubMed ID: 19419018
    [No Abstract]   [Full Text] [Related]  

  • 22. [Treatment and follow-up of superficial bladder cancer].
    Raitanen M
    Duodecim; 2002; 118(9):903-9. PubMed ID: 12238168
    [No Abstract]   [Full Text] [Related]  

  • 23. Staging and terminology of superficial urinary bladder tumors.
    Cannon SB
    J Insur Med; 2001; 33(4):360-2. PubMed ID: 11877919
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prostatic transitional cell carcinoma: pathologic features and clinical management.
    Shen SS; Lerner SP
    Expert Rev Anticancer Ther; 2007 Aug; 7(8):1155-62. PubMed ID: 18028024
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Pathologic anatomy of superficial tumors of the bladder].
    Billerey C; Sibony M; Gattegno B; Chopin D
    Prog Urol; 2001 Nov; 11(5):805-63. PubMed ID: 11769082
    [No Abstract]   [Full Text] [Related]  

  • 26. Pathologic assessment and clinical significance of prostatic involvement by transitional cell carcinoma and prostate cancer.
    Lerner SP; Shen S
    Urol Oncol; 2008; 26(5):481-5. PubMed ID: 18774459
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Therapeutic approach to bladder cancer classified as T3].
    Burette R
    Cancer Radiother; 1998 Apr; 2 Suppl 1():16s. PubMed ID: 9749071
    [No Abstract]   [Full Text] [Related]  

  • 28. Alternative therapies for bladder carcinoma.
    Marshall M; Price SE; Barnhouse DH; Powell JR
    Pa Med; 1987 May; 90(5):76-8. PubMed ID: 3587987
    [No Abstract]   [Full Text] [Related]  

  • 29. Advanced bladder cancer in a young female: a case report.
    Masuda A; Minakmi S; Usui Y; Arihara K; Nagata Y; Kawamura N
    Tokai J Exp Clin Med; 2001 Jul; 26(2):39-43. PubMed ID: 11806441
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Results of therapy in different groups of risk for superficial bladder cancer].
    Startsev VIu; Gorelov SI; Pulin IL; Merkur'eva RD; Ogava I
    Vopr Onkol; 2006; 52(2):187-91. PubMed ID: 17195646
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pathology and staging of bladder cancer.
    Bane BL; Rao JY; Hemstreet GP
    Semin Oncol; 1996 Oct; 23(5):546-70. PubMed ID: 8893867
    [No Abstract]   [Full Text] [Related]  

  • 32. Re: patterns of initial transitional cell recurrence in patients after cystectomy.
    Zaghloul MS
    J Urol; 2007 Aug; 178(2):730; author reply 730. PubMed ID: 17574607
    [No Abstract]   [Full Text] [Related]  

  • 33. Outcome and patterns of recurrence of nonbilharzial pure squamous cell carcinoma of the bladder: a contemporary review of The University of Texas M D Anderson Cancer Center experience.
    Kassouf W; Spiess PE; Siefker-Radtke A; Swanson D; Grossman HB; Kamat AM; Munsell MF; Guo CC; Czerniak BA; Dinney CP
    Cancer; 2007 Aug; 110(4):764-9. PubMed ID: 17614317
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical panurothelial disease in patients with superficial bladder tumors: therapeutic implications.
    Solsona E; Iborra I; Ricos JV; Monros JL; Rubio J; Almenar S
    J Urol; 2002 May; 167(5):2007-11. PubMed ID: 11956428
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Estimation of the true number of lymph nodes in lymphadenectomy specimens from radical cystectomy.
    Jensen JB; Ulhøi BP; Jensen KM
    Scand J Urol Nephrol; 2009; 43(4):288-92. PubMed ID: 19437191
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Systematic histologic urinary bladder mapping in primary urinary bladder cancers].
    Theuring F; Theuring U
    Pathologe; 1990 May; 11(3):148-53. PubMed ID: 2374761
    [No Abstract]   [Full Text] [Related]  

  • 37. Association of statin use with improved local control in patients treated with selective bladder preservation for muscle-invasive bladder cancer.
    Tsai HK; Katz MS; Coen JJ; Zietman AL; Kaufman DS; Shipley WU
    Urology; 2006 Dec; 68(6):1188-92. PubMed ID: 17141846
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recurrence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guerin.
    Brake M; Loertzer H; Horsch R; Keller H
    J Urol; 2000 Jun; 163(6):1697-701. PubMed ID: 10799163
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Are bladder cancer patients with pT0 disease following radical cystectomy cured of cancer?
    Thalmann G
    Nat Clin Pract Urol; 2006 Oct; 3(10):530-1. PubMed ID: 17031377
    [No Abstract]   [Full Text] [Related]  

  • 40. [New information in the classification of urothelial tumors of the bladder].
    Guillou L
    Ann Pathol; 1999; 19(5 Suppl):S103-7. PubMed ID: 10599468
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.